GSK Stock - FDA clears Utebzi as first oral carbapenem

GSK stock has a fresh pipeline win to point to after the U.S. FDA approved Utebzi, the first oral carbapenem for certain adults with complicated urinary tract infections, even as the shares underperformed the FTSE 100 over the past week.

Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 18:32 CET. Details in the imprint.

GSK (GB0009252882) has a new regulatory milestone in its antibiotics portfolio. The U.S. Food and Drug Administration has approved Utebzi, described as the first oral carbapenem antibiotic for certain adults with complicated urinary tract infections, according to a London market summary dated June 20, 2026.

What the FDA decision changes

The June 20 market note from London highlights that Utebzi, also known as tebipenem pivoxil, has received a U.S. green light as the first oral carbapenem option for some adults with complicated urinary tract infections and kidney infections.

According to that briefing, the medicine is aimed at adults who have few existing oral treatment alternatives, with GSK planning a U.S. launch by the end of 2026. Amanda Peppercorn, who leads the program at GSK, is cited as saying the drug serves patients “within the carbapenem footprint” by offering an oral route.

How GSK shares reacted this week

The same London summary reports that GSK shares ended Friday at 1,925.5 pence, edging up 0.1% on the session but slipping about 3% for the week, while the FTSE 100 fell roughly 1% over that period.

That means GSK underperformed the broader index by around two percentage points in the week of the FDA decision, with the note pointing out that shares fell in the aftermath of the pipeline win even as the company secured a novel oral antibiotic approval.

How GSK makes its money

GSK generates revenue primarily from prescription medicines, vaccines and specialty therapies, with marketed products including shingles vaccine Shingrix, respiratory treatment Trelegy and meningitis vaccines, alongside its growing portfolio of infectious disease and HIV medicines.

Where the stock trades today

The shares of GSK (GB0009252882) trade on the London Stock Exchange at 1,925.5 pence as of 06/19/2026, 16:03 BST.

Key facts on GSK stock

• Company: GSK plc
• ISIN: GB0009252882
• WKN: 940561
• Ticker: GSK
• Venue: London Stock Exchange
• Price (as of 06/19/2026, 16:03 BST): 1,925.5 pence
• Market cap: 77,000,000,000 GBP (as of 06/19/2026)
• Sector / Industry: Health Care / Pharmaceuticals & Biotechnology
• Index membership: FTSE 100
• Next earnings date: 07/28/2026

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.